{"id":"al01211","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL6068534","moleculeType":"Small molecule","molecularWeight":"542.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AL01211 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"AL01211 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:33.924Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06114329","phase":"PHASE2","title":"Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease","status":"RECRUITING","sponsor":"AceLink Therapeutics, Inc.","startDate":"2023-10-25","conditions":"Fabry Disease","enrollment":16},{"nctId":"NCT04908462","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers","status":"COMPLETED","sponsor":"AceLink Therapeutics, Inc.","startDate":"2021-06-08","conditions":"Autosomal Dominant Polycystic Kidney","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AL01211","genericName":"AL01211","companyName":"AceLink Therapeutics, Inc.","companyId":"acelink-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL01211 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}